Peripheral Blood Transcriptome in Breast Cancer Patients as a Source of Less Invasive Immune Biomarkers for Personalized Medicine, and Implications for Triple Negative Breast Cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Peripheral Blood Transcriptome in Breast Cancer Patients as a Source of Less Invasive Immune Biomarkers for Personalized Medicine, and Implications for Triple Negative Breast Cancer
Authors
Keywords
-
Journal
Cancers
Volume 14, Issue 3, Pages 591
Publisher
MDPI AG
Online
2022-01-26
DOI
10.3390/cancers14030591
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- FDA Approves Pembrolizumab + Chemotherapy Combination for Locally Recurrent Unresectable or Metastatic TNBC
- (2021) Hannah Slater ONCOLOGY-NEW YORK
- Immune Infiltrates in Breast Cancer: Recent Updates and Clinical Implications
- (2021) Maria Vittoria Dieci et al. Cells
- Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
- (2021) Hyuna Sung et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers
- (2021) M. F. Tolba et al. Clinical & Translational Oncology
- FDA Approval Summary: Fam-trastuzumab deruxtecan-nxki for the treatment of unresectable or metastatic HER2-positive breast cancer
- (2021) Preeti Narayan et al. CLINICAL CANCER RESEARCH
- Soluble Neuropilin-1 is an independent marker of poor prognosis in early breast cancer
- (2021) Tilman D. Rachner et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- Platelets, immune cells and the coagulation cascade; friend or foe of the circulating tumour cell?
- (2021) Mark P. Ward et al. Molecular Cancer
- Immune-related biomarkers in triple-negative breast cancer
- (2021) Juan Zhang et al. Breast Cancer
- Clinical Outcomes for Patients With Metastatic Breast Cancer Treated With Immunotherapy Agents in Phase I Clinical Trials
- (2021) Anna R. Schreiber et al. Frontiers in Oncology
- First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis
- (2021) L.A. Emens et al. ANNALS OF ONCOLOGY
- Application of HER2 peptide vaccines in patients with breast cancer: a systematic review and meta-analysis
- (2021) Zicong You et al. Cancer Cell International
- Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer
- (2021) Clinton Yam et al. CLINICAL CANCER RESEARCH
- Trastuzumab-lapatinib as neoadjuvant therapy for HER2-positive early breast cancer: Survival analyses of the CHER-Lob trial
- (2021) Valentina Guarneri et al. EUROPEAN JOURNAL OF CANCER
- Peripheral blood transcriptome heterogeneity and prognostic potential in lung cancer revealed by RNA‐Seq
- (2021) Qi Zhang et al. JOURNAL OF CELLULAR AND MOLECULAR MEDICINE
- Preliminary data on antitumor activity of extracorporeal subtraction of soluble TNFRs to unleash the activity of endogenous TNFα combined with chemotherapy in treatment-refractory, advanced, triple-negative breast cancer patients.
- (2021) Piotr Jan Wysocki et al. JOURNAL OF CLINICAL ONCOLOGY
- Doxorubicin–paclitaxel sequential treatment: insights of DNA methylation and gene expression changes of luminal A and triple negative breast cancer cell lines
- (2021) Lama Hamadneh et al. MOLECULAR AND CELLULAR BIOCHEMISTRY
- Tumor-Induced Inflammatory Cytokines and the Emerging Diagnostic Devices for Cancer Detection and Prognosis
- (2021) Apriliana E. R. Kartikasari et al. Frontiers in Oncology
- Platelet-to-Lymphocyte Ratio Is Associated With Favorable Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: A Study on 120 Patients
- (2021) Sejdi Lusho et al. Frontiers in Oncology
- Current Triple-Negative Breast Cancer Subtypes: Dissecting the Most Aggressive Form of Breast Cancer
- (2021) Miquel Ensenyat-Mendez et al. Frontiers in Oncology
- Engineering Breast Cancer On-chip—Moving Toward Subtype Specific Models
- (2021) Carmen Moccia et al. Frontiers in Bioengineering and Biotechnology
- Recent Progress on Immunotherapy for Breast Cancer: Tumor Microenvironment, Nanotechnology and More
- (2021) Yang Li et al. Frontiers in Bioengineering and Biotechnology
- Recurrence biomarkers of triple negative breast cancer treated with neoadjuvant chemotherapy and anti-EGFR antibodies
- (2021) Nina Radosevic-Robin et al. npj Breast Cancer
- 25P Early detection of breast cancer by liquid biopsy exploiting the DNA damage sensitivity (DDS)
- (2021) R. Nussbaumer et al. ANNALS OF ONCOLOGY
- FDA Approval Summary: Margetuximab plus Chemotherapy for Advanced or Metastatic HER2-Positive Breast Cancer
- (2021) Melanie Royce et al. CLINICAL CANCER RESEARCH
- Cancer vaccines as a targeted immunotherapy approach for breast cancer: an update of clinical evidence
- (2021) Maryam Abbaspour et al. Expert Review of Vaccines
- DNA methylation and breast cancer: A way forward (Review)
- (2021) Maria Vietri et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Comparison of four methods of colon cancer cell lysates preparation for ex vivo maturation of dendritic cells
- (2021) Vajihe Akbari et al. Research in Pharmaceutical Sciences
- Pembrolizumab plus chemotherapy as neoadjuvant treatment for high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
- (2020) P. Schmid et al. ANNALS OF ONCOLOGY
- Integrating DNA methylation measures to improve clinical risk assessment: are we there yet? The case of BRCA1 methylation marks to improve clinical risk assessment of breast cancer
- (2020) Ee Ming Wong et al. BRITISH JOURNAL OF CANCER
- FDA Approval Summary: Atezolizumab plus paclitaxel protein-bound for the treatment of patients with advanced or metastatic TNBC whose tumors express PD-L1
- (2020) Preeti Narayan et al. CLINICAL CANCER RESEARCH
- High-dimensional immune-profiling in cancer: implications for immunotherapy
- (2020) Samuel Chuah et al. Journal for ImmunoTherapy of Cancer
- Breast cancer induces systemic immune changes on cytokine signaling in peripheral blood monocytes and lymphocytes
- (2020) Lei Wang et al. EBioMedicine
- FDA Approval Summary: Ado-trastuzumab emtansine for the adjuvant treatment of HER2-positive early breast cancer
- (2020) Suparna Wedam et al. CLINICAL CANCER RESEARCH
- KEYNOTE-355: Randomized, double-blind, phase III study of pembrolizumab + chemotherapy versus placebo + chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer.
- (2020) Javier Cortes et al. JOURNAL OF CLINICAL ONCOLOGY
- Identification of human peripheral blood monocyte gene markers for early screening of solid tumors
- (2020) Siyang Chen et al. PLoS One
- PBMCs: a new source of diagnostic and prognostic biomarkers
- (2020) Meysam Mosallaei et al. ARCHIVES OF PHYSIOLOGY AND BIOCHEMISTRY
- Breast Fibroblasts and ECM Components Modulate Breast Cancer Cell Migration through the Secretion of MMPs in a 3D Microfluidic Co-Culture Model
- (2020) Karina M. Lugo-Cintrón et al. Cancers
- Platelet-Leukocyte Interplay in Cancer Development and Progression
- (2020) Dagmar Stoiber et al. Cells
- The Expression Level of PD-L1 (CD274) mRNA in Peripheral Blood Is a Potential Biomarker for Predicting Recurrence in Breast Cancer
- (2020) TAKAAKI MASUDA et al. ANTICANCER RESEARCH
- Neuropilins, as Relevant Oncology Target: Their Role in the Tumoral Microenvironment
- (2020) Aurore Dumond et al. Frontiers in Cell and Developmental Biology
- Changes in Peripheral and Local Tumor Immunity after Neoadjuvant Chemotherapy Reshape Clinical Outcomes in Patients with Breast Cancer
- (2020) Margaret L. Axelrod et al. CLINICAL CANCER RESEARCH
- Metastatic Breast Cancer and Pre-Diagnostic Blood Gene Expression Profiles—The Norwegian Women and Cancer (NOWAC) Post-Genome Cohort
- (2020) Einar Holsbø et al. Frontiers in Oncology
- Molecular intrinsic versus clinical subtyping in breast cancer: A comprehensive review
- (2020) Agata Szymiczek et al. CLINICAL GENETICS
- Epigenetics in Breast Cancer Therapy—New Strategies and Future Nanomedicine Perspectives
- (2020) Verona Buocikova et al. Cancers
- Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers
- (2019) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Human Tumor-Associated Macrophage and Monocyte Transcriptional Landscapes Reveal Cancer-Specific Reprogramming, Biomarkers, and Therapeutic Targets
- (2019) Luca Cassetta et al. CANCER CELL
- Usefulness of the nCounter Analysis System to Monitor Immune-related Biomarkers in PBMCs During Anti-PD-1 Therapy
- (2019) TAKAFUMI MORISAKI et al. ANTICANCER RESEARCH
- Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer
- (2019) Shaveta Vinayak et al. JAMA Oncology
- CAR-T Engineering: Optimizing Signal Transduction and Effector Mechanisms
- (2019) Emiliano Roselli et al. BIODRUGS
- Immune Profiles of Tumor Microenvironment and Clinical Prognosis among Women with Triple-Negative Breast Cancer
- (2019) Ling Deng et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- BRCA1 promoter methylation in peripheral blood is associated with the risk of triple‐negative breast cancer
- (2019) Karolina Prajzendanc et al. INTERNATIONAL JOURNAL OF CANCER
- PD‑L1 expression levels on tumor cells affect their immunosuppressive activity
- (2019) Yang Zheng et al. Oncology Letters
- The Immune Microenvironment of Breast Cancer Progression
- (2019) Tower et al. Cancers
- Two Distinct Subtypes Revealed in Blood Transcriptome of Breast Cancer Patients With an Unsupervised Analysis
- (2019) Wenlong Ming et al. Frontiers in Oncology
- Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial
- (2019) Peter Schmid et al. LANCET ONCOLOGY
- TH9, TH17, and TH22 Cell Subsets and Their Main Cytokine Products in the Pathogenesis of Colorectal Cancer
- (2019) Guanglin Cui Frontiers in Oncology
- Prognostic value of tumor-infiltrating lymphocytes in patients with early-stage triple-negative breast cancers (TNBC) who did not receive adjuvant chemotherapy
- (2019) J H Park et al. ANNALS OF ONCOLOGY
- Triple‐negative breast cancer—Role of immunology: A systemic review
- (2019) Gizem Oner et al. Breast Journal
- Transcriptomic Analyses Revealed Systemic Alterations in Gene Expression in Circulation and Tumor Microenvironment of Colorectal Cancer Patients
- (2019) Hibah Shaath et al. Cancers
- Triple negative breast cancer: Key role of Tumor-Associated Macrophages in regulating the activity of anti-PD-1/PD-L1 agents
- (2018) Matteo Santoni et al. BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER
- Cancer statistics, 2018
- (2018) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer
- (2018) Ana Costa et al. CANCER CELL
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- (2018) Carsten Denkert et al. LANCET ONCOLOGY
- Single-cell RNA sequencing for the study of development, physiology and disease
- (2018) S. Steven Potter Nature Reviews Nephrology
- Immune-Phenotyping and Transcriptomic Profiling of Peripheral Blood Mononuclear Cells From Patients With Breast Cancer: Identification of a 3 Gene Signature Which Predicts Relapse of Triple Negative Breast Cancer
- (2018) Gemma A. Foulds et al. Frontiers in Immunology
- Gene expression profile of peripheral blood mononuclear cells may contribute to the identification and immunological classification of breast cancer patients
- (2018) Eiji Suzuki et al. Breast Cancer
- Molecular alterations in triple-negative breast cancer—the road to new treatment strategies
- (2017) Carsten Denkert et al. LANCET
- HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial
- (2017) Antonio Llombart-Cussac et al. LANCET ONCOLOGY
- Interactions between the tumor and the blood systemic response of breast cancer patients
- (2017) Vanessa Dumeaux et al. PLoS Computational Biology
- Neuropilin-1 Associated Molecules in the Blood Distinguish Poor Prognosis Breast Cancer: A Cross-Sectional Study
- (2017) Adviti Naik et al. Scientific Reports
- Dendritic Cell Vaccination Enhances Immune Responses and Induces Regression of HER2 pos DCIS Independent of Route: Results of Randomized Selection Design Trial
- (2016) Lea Lowenfeld et al. CLINICAL CANCER RESEARCH
- Carcinoma-associated fibroblasts: orchestrating the composition of malignancy
- (2016) Philippe Gascard et al. GENES & DEVELOPMENT
- Blood Genome-Wide Transcriptional Profiles of HER2 Negative Breast Cancers Patients
- (2016) Ovidiu Balacescu et al. MEDIATORS OF INFLAMMATION
- Blood-based DNA methylation as biomarker for breast cancer: a systematic review
- (2016) Qiuqiong Tang et al. Clinical Epigenetics
- Limits of Peripheral Blood Mononuclear Cells for Gene Expression-Based Biomarkers in Juvenile Idiopathic Arthritis
- (2016) Laiping Wong et al. Scientific Reports
- Human breast cancer invasion and aggression correlates with ECM stiffening and immune cell infiltration
- (2015) I. Acerbi et al. Integrative Biology
- Baseline blood immunological profiling differentiates between Her2– breast cancer molecular subtypes: implications for immunomediated mechanisms of treatment response
- (2015) Oana Tudoran et al. OncoTargets and Therapy
- Gene expression profiling of circulating tumor cells and peripheral blood mononuclear cells from breast cancer patients
- (2015) Michal Hensler et al. OncoImmunology
- Remodeling Components of the Tumor Microenvironment to Enhance Cancer Therapy
- (2015) Vasiliki Gkretsi et al. Frontiers in Oncology
- Discovery of a 29-Gene Panel in Peripheral Blood Mononuclear Cells for the Detection of Colorectal Cancer and Adenomas Using High Throughput Real-Time PCR
- (2015) Laura Ciarloni et al. PLoS One
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- Peripheral blood cells inform on the presence of breast cancer: A population-based case-control study
- (2014) Vanessa Dumeaux et al. INTERNATIONAL JOURNAL OF CANCER
- Host Antitumor Immunity Plays a Role in the Survival of Patients With Newly Diagnosed Triple-Negative Breast Cancer
- (2014) Sherene Loi JOURNAL OF CLINICAL ONCOLOGY
- Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
- (2014) Sylvia Adams et al. JOURNAL OF CLINICAL ONCOLOGY
- Differential Peripheral Blood Gene Expression Profile Based on Her2 Expression on Primary Tumors of Breast Cancer Patients
- (2014) Oana Tudoran et al. PLoS One
- PD-L1 Expression in Triple-Negative Breast Cancer
- (2014) E. A. Mittendorf et al. Cancer Immunology Research
- The presence of programmed death 1 (PD-1)-positive tumor-infiltrating lymphocytes is associated with poor prognosis in human breast cancer
- (2013) S. Muenst et al. BREAST CANCER RESEARCH AND TREATMENT
- Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer
- (2013) A N Seo et al. BRITISH JOURNAL OF CANCER
- Molecular Characterization of Basal-Like and Non-Basal-Like Triple-Negative Breast Cancer
- (2013) A. Prat et al. ONCOLOGIST
- The presence of tumor associated macrophages in tumor stroma as a prognostic marker for breast cancer patients
- (2012) Catharina Medrek et al. BMC CANCER
- Comprehensive molecular portraits of human breast tumours
- (2012) Daniel C. Koboldt et al. NATURE
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies
- (2011) Brian D. Lehmann et al. JOURNAL OF CLINICAL INVESTIGATION
- Triple-Negative Subtype Predicts Poor Overall Survival and High Locoregional Relapse in Inflammatory Breast Cancer
- (2011) J. Li et al. ONCOLOGIST
- Constitutional Methylation of the BRCA1 Promoter Is Specifically Associated with BRCA1 Mutation-Associated Pathology in Early-Onset Breast Cancer
- (2010) E. M. Wong et al. Cancer Prevention Research
- RNA sequencing: advances, challenges and opportunities
- (2010) Fatih Ozsolak et al. NATURE REVIEWS GENETICS
- Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies
- (2010) Fiona M. Blows et al. PLOS MEDICINE
- FOXP3+ Tregs and B7-H1+/PD-1+T lymphocytes co-infiltrate the tumor tissues of high-risk breast cancer patients: Implication for immunotherapy
- (2008) Hazem Ghebeh et al. BMC CANCER
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started